Bausch Health Companies Inc. reported a total asset decrease to $25.48 billion as of September 30, 2026, compared to $26.37 billion at year-end 2025, primarily driven by a reduction in goodwill and intangible assets. The company's total shareholders' deficit widened to $1.33 billion, while cash and cash equivalents significantly increased to $2.49 billion.
Bausch Health reported third quarter 2026 consolidated revenues of $2.94 billion, a 10% increase over the prior year, and GAAP net income of $446 million. The company achieved a milestone with quarterly Adjusted EBITDA (excluding Bausch + Lomb) exceeding $1 billion for the first time and raised its full-year 2026 guidance across revenue and EBITDA metrics.
Term
Q3 2026
“Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation.”
Thomas J. Appio, Chief Executive Officer, Bausch Health